A. Fieuw

发表

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial.

S. Dupont, W. Wuyts, T. Maher, 2018, The Lancet. Respiratory medicine.

The microRNA body map: dissecting microRNA function through integrative genomics

Filip Pattyn, Frank Speleman, Pieter Mestdagh, 2011, Nucleic acids research.

Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis

A. Taneja, P. Diderichsen, E. M. van der Aar, 2019, Clinical Pharmacokinetics.

Belgian global implementation of cardiovascular and stroke risk assessment study: methods and baseline data of the BELGICA-STROKE STUDY

P. van de Borne, V. Thijs, M. Dramaix, 2011, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

Focus on 16p13.3 Locus in Colon Cancer

P. Pattyn, K. Claes, N. Van Roy, 2015, PloS one.

Identification of a novel recurrent 1q42.2‐1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas

Peter H. Sudmant, F. Antonacci, P. Sudmant, 2012, International journal of cancer.

Outcome of publicly funded nationwide first-tier noninvasive prenatal screening

K. Devriendt, B. Menten, J. Vermeesch, 2021, Genetics in Medicine.

Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis.

S. Nathan, L. Lancaster, P. Ford, 2020, Contemporary clinical trials.

Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes

F. Westermann, F. Speleman, B. Menten, 2013, PloS one.

Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials

S. Dupont, E. M. van der Aar, J. Desrivot, 2019, Journal of clinical pharmacology.

DNA Copy Number Changes and Beyond

F. Speleman, K. D. Preter, A. Fieuw, 2015 .

Prenatally detected copy number variants in a national cohort: A postnatal follow‐up study

K. Devriendt, B. Menten, J. Vermeesch, 2020, Prenatal diagnosis.

The need for transparency and good practices in the qPCR literature

Erik Willems, Jo Vandesompele, Jim Huggett, 2013, Nature Methods.

The Belgian MicroArray Prenatal (BEMAPRE) database: A systematic nationwide repository of fetal genomic aberrations

K. Devriendt, B. Menten, J. Vermeesch, 2018, Prenatal diagnosis.

The autotaxin-lysophosphatidic acid pathway mediates mesenchymal cell recruitment and fibrotic contraction in lung transplant fibrosis.

P. Ford, A. Fieuw, D. Chambers, 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)

M. Kreuter, K. Brown, W. Wuyts, 2019, BMJ Open Respiratory Research.

Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS‐5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip

S. Dupont, L. Lohmander, Staffan Larsson, 2021, Clinical pharmacology in drug development.

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.

G. Molenberghs, M. Kreuter, A. Taneja, 2023, JAMA.

Performance and Diagnostic Value of Genome-Wide Noninvasive Prenatal Testing in Multiple Gestations

K. Devriendt, J. Vermeesch, J. Gatot, 2021, Obstetrics and gynecology.

Cancer Gene Prioritization for Targeted Resequencing Using FitSNP Scores

F. Speleman, J. Vandesompele, K. De Preter, 2012, PloS one.